7,091 results on '"Atrophic gastritis"'
Search Results
2. Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer Mortality (GISTAR)
- Author
-
University of Latvia, Technion, Israel Institute of Technology, Karolinska Institutet, Academic Histology Laboratory (Latvia), and Vanderbilt University
- Published
- 2024
3. Atrophic Gastritis Predicts the Risk of Gastric Cancer
- Author
-
Hong Lu, MD, Medical Doctor of Division of Gastroenterology and Hepatology of Renji Hospital,Professor of Medicine
- Published
- 2024
4. The Diagnostic Value of Serum Trefoil Factor 3 and Pepsinogen combination in Chronic Atrophic Gastritis: A Retrospective Study Based on a Gastric Cancer Screening Cohort in the Community Population.
- Author
-
Zhao, Jiamin, Tian, Wenying, Zhang, Xiaoxue, Dong, Shengrong, Shen, Yao, Gao, Xiaojuan, Yang, Mei, Lv, Jiale, Hu, Feifan, Han, Jinglve, Zhan, Qiang, and An, Fangmei
- Subjects
- *
TREFOIL factors , *ATROPHIC gastritis , *HELICOBACTER pylori , *RECEIVER operating characteristic curves , *PEPSINOGEN - Abstract
Background and Aims: Chronic atrophic gastritis (CAG) is an important precursor of gastric cancer(GC), and there is currently a lack of reliable non-invasive diagnostic markers. This study aims to find a biomarker for non-invasive screening of CAG in the community.Methods: A total of 540 individuals were enrolled (test set = 385, validation set = 155). ROC curve analysis was used to evaluate the diagnostic significance of Trefoil Factor 3(TFF3) alone or in combination with pepsinogen (PG) for CAG in test and validation set. Furthermore, the diagnostic value of TFF3 and PG in different H. pylori infection states was studied.Results: When compared with the chronic superficial gastritis (CSG), the expression level of TFF3 in the CAG was higher (27ng/ml VS 19.61, P < 0.001). ROC curve analysis found that the sensitivity, specificity, and area under the curve (AUC) of CAG diagnosis using serum TFF3 alone at the optimal cut-off value of 26.55ng/ml were 0.529, 0.87, and 0.739, respectively. When TFF3 was combined with The Ratio of PGI to PGII (PGR), the AUC and specificity reached to 0.755 and 0.825 respectively. TFF3 individual or combined with PGR had good predictive value especially in the H. Pylori negative patients.Conclusion: TFF3 combined with PGR can effectively predict CAG especially in the patients with H. pylori negative. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
5. Protein Biomarkers of Gastric Preneoplasia and Cancer Lesions in Blood: A Comprehensive Review.
- Author
-
Bazin, Thomas, Nozeret, Karine, Julié, Catherine, Lamarque, Dominique, and Touati, Eliette
- Subjects
- *
STOMACH tumors , *NEOPLASTIC cell transformation , *PRECANCEROUS conditions , *BLOOD proteins , *AUTOANTIBODIES , *TUMOR markers , *METASTASIS , *ATROPHIC gastritis , *INTESTINAL tumors , *ENDOSCOPIC gastrointestinal surgery , *INFLAMMATION , *SIGNAL peptides , *DISEASE complications ,BODY fluid examination - Abstract
Simple Summary: Gastric cancer (GC) is a major cause of mortality worldwide. It is preceded by the progressive development of lesions of the gastric mucosa, namely atrophic gastritis, intestinal metaplasia, and dysplasia, collectively referred to preneoplasia. Periodic monitoring has been proposed for the surveillance of intestinal metaplasia and dysplasia. However, endoscopy, the current gold standard in GC diagnosis, has a limited ability to detect gastric preneoplasia, especially in early stages. In order to overcome the limitations of endoscopy screening, the potential of blood biomarkers has been investigated, and some biomarkers have been identified consistently across different studies. Nevertheless, validation studies in specific populations must be conducted before these results can allow the design of non-invasive tests to be translated into clinical practice for the early detection of patients at risk of developing GC. Gastric cancer (GC) is a major cause of cancer-related mortality worldwide. It is often associated with a bad prognosis because of its asymptomatic phenotype until advanced stages, highlighting the need for its prevention and early detection. GC development is preceded by the emergence of gastric preneoplasia lesions (GPNLs), namely atrophic gastritis (AG), intestinal metaplasia (IM), and dysplasia (DYS). GC is currently diagnosed by endoscopy, which is invasive and costly and has limited effectiveness for the detection of GPNLs. Therefore, the discovery of non-invasive biomarkers in liquid biopsies, such as blood samples, in order to identify the presence of gastric preneoplasia and/or cancer lesions at asymptomatic stages is of paramount interest. This comprehensive review provides an overview of recently identified plasma/serum proteins and their diagnostic performance for the prediction of GPNLs and early cancer lesions. Autoantibodies appear to be promising biomarkers for AG, IM and early gastric cancer detection, along with inflammation and immunity-related proteins and antibodies against H. pylori virulence factors. There is a lack of specific protein biomarkers with which to detect DYS. Despite the need for further investigation and validation, some emerging candidates could pave the way for the development of reliable, non-invasive diagnostic tests for the detection and prevention of GC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Gastric microbiome signature for predicting metachronous recurrence after endoscopic resection of gastric neoplasm.
- Author
-
Lee, Ho-Kyoung, Shin, Cheol Min, Chang, Young Hoon, Yoon, Hyuk, Park, Young Soo, Kim, Nayoung, and Lee, Dong Ho
- Subjects
- *
HELICOBACTER pylori infections , *ENDOSCOPIC surgery , *GASTRECTOMY , *ATROPHIC gastritis , *RIBOSOMAL DNA - Abstract
Background: Changes in gastric microbiome are associated with gastric carcinogenesis. Studies on the association between gastric mucosa-associated gastric microbiome (MAM) and metachronous gastric cancer are limited. This study aimed to identify gastric MAM as a predictive factor for metachronous recurrence following endoscopic resection of gastric neoplasms. Method: Microbiome analyses were conducted for 81 patients in a prospective cohort to investigate surrogate markers to predict metachronous recurrence. Gastric MAM in non-cancerous corporal biopsy specimens was evaluated using Illumina MiSeq platform targeting 16S ribosomal DNA. Results: Over a median follow-up duration of 53.8 months, 16 metachronous gastric neoplasms developed. Baseline gastric MAM varied with Helicobacter pylori infection status, but was unaffected by initial pathologic diagnosis, presence of atrophic gastritis, intestinal metaplasia, or synchronous lesions. The group with metachronous recurrence did not exhibit distinct phylogenetic diversity compared with the group devoid of recurrence but showed significant difference in β-diversity. The study population could be classified into two distinct gastrotypes based on baseline gastric MAM: gastrotype 1, Helicobacter-abundant; gastrotype 2: Akkermansia-abundant. Patients in gastrotype 2 showed higher risk of metachronous recurrence than gastrotype (Cox proportional hazard analysis, adjusted hazard ratio [95% confidence interval]: 5.10 [1.09–23.79]). Conclusions: Gastric cancer patients can be classified into two distinct gastrotype groups by their MAM profiles, which were associated with different risk of metachronous recurrence. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Pro- and anti-inflammatory cytokines: the hidden keys to autoimmune gastritis therapy.
- Author
-
Cascetta, Greta, Colombo, Giorgia, Eremita, Gianmarco, Garcia, Joe G. N., Lenti, Marco Vincenzo, Di Sabatino, Antonio, and Travelli, Cristina
- Subjects
ATROPHIC gastritis ,AUTOIMMUNE diseases ,GASTRITIS ,NEUROENDOCRINE tumors ,IMMUNE system - Abstract
Autoimmune gastritis (AIG) is an autoimmune disorder characterized by the destruction of gastric parietal cells and atrophy of the oxyntic mucosa which induces intrinsic factor deficiency and hypo-achlorhydria. AIG predominantly affects the antral mucosa with AIG patients experiencing increased inflammation and a predisposition toward the development of gastric adenocarcinoma and type I neuroendocrine tumors. The exact pathogenesis of this autoimmune disorder is incompletely understood although dysregulated immunological mechanisms appear to major contributors. This review of autoimmune gastritis, an unmet medical need, summarizes current knowledge on pro- and anti-inflammatory cytokines and strategies for the discovery of novel biomarkers and potential pharmacological targets. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Overall and cause-specific mortality among patients diagnosed with gastric precancerous lesions in Sweden between 1979 and 2014: an observational cohort study.
- Author
-
Sun, Yawen, Yin, Li, Nesheli, Dariush Nasrollahzadeh, Yu, Jingru, Franzén, Joar, and Ye, Weimin
- Subjects
- *
DIGESTIVE system diseases , *PARASITIC diseases , *ATROPHIC gastritis , *CANCER-related mortality , *RESPIRATORY diseases - Abstract
Background: The Correa's cascade, encompassing chronic non-atrophic gastritis, atrophic gastritis, intestinal metaplasia, and dysplasia, represents the well-recognized pathway for the development of non-cardia gastric cancer. Population-based studies on all-cause and cause-specific mortalities among patients with gastric lesions in Correa's cascade are scarce. Methods: We compiled a cohort of 340 744 eligible patients who had undergone endoscopy with biopsy for non-malignant indications during the period 1979–2011, which was followed up until 2014. Standardized mortality ratios (SMRs) with 95% confidence intervals (CIs) provided estimation of the relative risk, using the general Swedish population as reference. Cox regression model was used to estimate hazard ratios (HRs) of death for internal comparison. Results: A total of 306 117 patients were included in the final analysis, accumulating 3,049,009 person-years of follow-up. In total 106,625 deaths were observed during the study period. Compared to the general population, excess risks of overall mortality were noted in all subgroups, with SMRs ranging from 1.11 (95% CI 1.08–1.14) for the normal mucosa group to 1.54 (95% CI 1.46–1.62) for the dysplasia group. For cause-specific mortalities, mortality from gastric cancer gradually increased along Correa's cascade, with excess risk rising from 105% for patients with chronic gastritis to more than 600% for the dysplasia group. These results were confirmed in the comparison with the normal mucosa group. For non-cancer conditions, increased death risks were noted for various diseases compared to the general population, especially among patients with more severe gastric precancerous lesions. But the results were confirmed only for "infectious diseases and parasitic diseases", "respiratory system diseases", and "digestive system disease", when using the normal mucosa group as reference. Conclusions: Increased mortality from gastric cancer suggests that early recognition and intervention of gastric precancerous lesions probably benefit the patients. Excess mortality due to non-cancer conditions should be interpreted with caution, and future studies are warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Improving the Diagnosis of Autoimmune Gastritis: From Parietal Cell Antibodies to H+/K+ ATPase Antibodies.
- Author
-
Tonegato, Michela, Panozzo, Maria Piera, Antico, Antonio, and Bizzaro, Nicola
- Subjects
- *
ATROPHIC gastritis , *PARIETAL cells , *ENZYME-linked immunosorbent assay , *IMMUNOASSAY , *AUTOANTIBODIES - Abstract
Parietal cell autoantibodies (PCAs), which recognize the enzyme H+/K+-ATPase as a target, are considered to be a diagnostic marker of autoimmune gastritis and pernicious anemia; these conditions are characterized by the presence of corpus atrophic gastritis. Circulating PCAs can be detected using several analytical methods that are commonly available in the clinical laboratory. Traditionally, indirect immunofluorescence (IIF) on rodent or primate stomach tissue is used as a screening test for the detection of PCAs. However, IIF suffers from a high inter-observer variability and lacks standardization. In addition, like immunoblotting, results are expressed only in a qualitative or semi-quantitative manner. Based on the few available studies that are reviewed herein, quantitative enzyme-linked immunosorbent assays (ELISAs) and fluorescence enzyme immunoassays (FEIAs) using purified H+/K+-ATPase perform better than IIF in the detection of PCAs, displaying higher sensitivity and utility in monitoring the disease. In light of their higher diagnostic accuracy, these solid-phase methods should be preferred to IIF in the screening of autoimmune atrophic gastritis. The use of methods to detect antibodies versus a specific subunit of H+/K+-ATPase (α or β) is currently confined to the world of research. Further investigation is required to define the clinical utility of H+/K+-ATPase subunit detection. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Research on Predictive Auxiliary Diagnosis Method for Gastric Cancer Based on Non-Invasive Indicator Detection.
- Author
-
Zhang, Xia, Zhang, Mao, Wei, Gang, and Wang, Jia
- Subjects
RANDOM forest algorithms ,ATROPHIC gastritis ,ELECTRONIC health records ,LIVER function tests ,BLOOD testing - Abstract
Featured Application: The methodology and findings can be used as a basis for further research into other predictive models for various diseases, contributing to the advancement of predictive analytics in healthcare. Chronic atrophic gastritis is a serious health issue beyond the stomach health problems that affect normal life. This study aimed to explore the influencing factors related to chronic atrophic gastritis (CAG) using non-invasive indicators and establish an optimal prediction model to aid in the clinical diagnosis of CAG. Electronic medical record data from 20,615 patients with CAG were analyzed, including routine blood tests, liver function tests, and coagulation tests. The logistic regression algorithm revealed that age, hematocrit, and platelet distribution width were significant influences suggesting chronic atrophic gastritis in the Chongqing population (p < 0.05), with an area under the curve (AUC) of 0.879. The predictive model constructed based on the Random Forest algorithm exhibited an accuracy of 83.15%, precision of 97.38%, recall of 77.36%, and an F1-score of 70.86%, outperforming the models constructed using XGBoost, KNN, and SVC algorithms in a comprehensive comparison. The prediction model derived from this study serves as a valuable tool for future studies and can aid in the prediction and screening of chronic atrophic gastritis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Case report: Managing pemphigus foliaceus using apremilast without systemic glucocorticosteroids or immunosuppressive agents.
- Author
-
Quanhong Zhang, Lang Yu, Li Wan, Liuqing Chen, and Jinbo Chen
- Subjects
REGULATORY T cells ,PEMPHIGUS vulgaris ,ENZYME-linked immunosorbent assay ,IMMUNOSUPPRESSIVE agents ,ATROPHIC gastritis ,PEMPHIGUS - Abstract
Pemphigus foliaceus (PF) is a superficial form of pemphigus. Treatment options for PF resemble pemphigus vulgaris, including glucocorticosteroids, immunosuppressive agents and rituximab et al. These treatment approaches can effectively improve the condition but may also be accompanied by high risks of side effects. Therefore, it is crucial to find a safe and effective treatment options for patients with PF. It will not only benefit/be necessary for patients who refuse glucocorticosteroids or immunosuppressive agents treatments, but also for patients who cannot be treated with glucocorticosteroids or immunosuppressive agents. Herein, we reported a case of PF that was treated with apremilast without systemic glucocorticosteroids or immunosuppressive agents. A 54-year-old woman presented with itchy erythema and erosions on the trunk for more than 1 month. The patient applied mometasonefuroate cream without improvement for a duration of two weeks. The past history of diabetes mellitus and atrophic gastritis was reported. Physical examination revealed scattered erythematous macules and erosions on the trunk. No mucosal involvement was observed. The condition was assessed by the pemphigus disease area index and numerical rating scale, with baseline scores of 7 and 8, respectively. Histopathological examination showed acantholysis and intraepithelial blister. Direct immunofluorescence revealed the presence of IgG and Complement 3 deposition between the acanthocytes with the reticular distribution. Based on enzyme-linked immunosorbent assay results, the levels of Dsg1 and Dsg3 antibodies were 28.18 and 0.26 kU/L respectively. The diagnosis of PF was made. This patient was successfully treated with apremilast without systemic glucocorticosteroids or immunosuppressive agents. The patient has continued with apremilast 30mg once daily for maintenance and no adverse events related to apremilast such as gastrointestinal side effects were observed during the 9-month follow-up period. In conclusion, apremilast therapy without systemic glucocorticosteroids nor immunosuppressive agents might provide an effective alternative to management of mild PF without obvious side effect. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Validity of rapid urease test using swab of gastric mucus to mucosal forceps and 13 C-urease breath test: a multicenter prospective observational study.
- Author
-
Yoshikawa, Takaaki, Yamauchi, Atsushi, Kou, Tadayuki, Murao, Takahisa, Kamada, Tomoari, Suehiro, Mitsuhiko, Kawano, Koichiro, Haruma, Ken, and Yazumi, Shujiro
- Subjects
- *
HELICOBACTER pylori , *ATROPHIC gastritis , *BREATH tests , *CONFIDENCE intervals , *FORCEPS - Abstract
Background: Theoretically, a rapid urease test (RUT) using a swab of the gastric wall (Swab-RUT) for Helicobacter pylori (H. pylori) is safe. However, the validity and utility of Swab-RUT remain unclear. Therefore, we assessed the validity and utility of Swab-RUT compared to RUT using mucosal forceps of the gastric wall (Forceps-RUT) and 13C-urea breath test (UBT). Methods: This study was a multicenter prospective observational study. When the examinees were suspected of H. pylori infection during esophagogastroduodenoscopy, we performed Swab-RUT and Forceps-RUT continuously. When the examinees were not suspected of H. pylori infection, we performed Swab-RUT alone. We validated the status of H. pylori infection using UBT. Results: Ninety-four examinees were enrolled from four institutions between May 2016 and December 2020 (median age [range], 56.5 [26–88] years). In this study, the sensitivity, specificity, and accuracy of Swab-RUT to UBT were 0.933 (95% confidence interval: 0.779–0.992), 0.922 (0.827–0.974), and 0.926 (0.853–0.970), respectively. The Kappa coefficient of Swab-RUT to UBT was 0.833, and that of Swab-RUT to forceps-RUT was 0.936. No complications were observed in this study. Conclusions: Swab-RUT is a valid examination for the status of H. pylori infection compared to the conventional Forceps-RUT. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Study of the association between the chemokine CXCL5 and the onset of chronic atrophic gastritis and gastric precancerous lesions.
- Author
-
PEI Bei, ZHANG Yi, SUN Qin, JIN Yueping, and LI Xuejun
- Subjects
- *
CHEMOKINES , *ATROPHIC gastritis , *PRECANCEROUS conditions , *HELICOBACTER pylori infections , *LOGISTIC regression analysis , *GENE expression - Abstract
Objective To clarify the changes in CXCL5 in serum and gastric tissues of patients with chronic atrophic gastritis (CAG) and precancerous lesions of gastric cancer (PLGC) and to investigate the predictive value of CXCL5 for the diagnosis of CAG and PLGC. Methods This study enrolled 72 participants of CAG admitted to the Department of Splenology and Gastroenterology of the Second Affiliated Hospital of Anhui University of Chinese Medicine from June 2022 to June 2023, with gastroscopy and pathologically confirmed diagnosis, as well as 68 healthy participants who underwent gastroscopy in the same period at our department. We collected clinical information and laboratory results from all participants. The logistic regression analysis methods were used to identify the diagnostic value of serum CXCL5. Furthermore, in order to clarify the role of CXCL5 in the development of CAG, a total of 15 patients each with CAG, intestinal metaplasia, and dysplasia treated at our hospital from June 2023 to December 2023, and 15 healthy participants were selected. The relationship between the expression of CXCL5 and the degree of clinicopathology was analysed in each group using ELISA, PCR, and immunohistochemistry staining to validate and assess the diagnostic efficacy of CXCL5. Results The study found that several factors were associated with CAG, including family history of tumours, smoking and alcohol consumption history, dietary regularity, Helicobacter pylori infection, the number of lesions, gastric function scores and CXCL5 (P < 0.05). The ROC curve had an AUC of 1.00 and a Youden index of 0.986, indicating excellent predictive ability. The ELISA results indicated a significantly higher serum CXCL5 expression level in the CAG, intestinal metaplasia, and dysplasia groups compared to the normal group. There was a positive correlation between the serum CXCL5 expression level and the degree of pathology. The PCR and immunohistochemistry staining results indicate that the mRNA and protein expression levels of CXCL5 in gastric tissues of patient groups were significantly higher compared to the normal group. Furthermore, the mRNA and protein expression levels of CXCL5 in gastric tissues were positively correlated with the degree of pathology. Conclusions The results indicate that CXCL5 is highly expressed in the serum and gastric tissues of patients with CAG and PLGC, and its expression level is positively correlated with the degree of pathology. Therefore, CXCL5 could serve as a predictive indicator and a potential therapeutic target for the diagnosis of CAG and PLGC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. Gastric Carcinogenesis and Potential Role of the Transient Receptor Potential Vanilloid 1 (TRPV1) Receptor: An Observational Histopathological Study.
- Author
-
Groen, Sylvester R., Keszthelyi, Daniel, Szallasi, Arpad, van Veghel, Jara A., Alleleyn, Annick M. E., Csekő, Kata, Helyes, Zsuzsanna, Samarska, Iryna, Grabsch, Heike I., Masclee, Ad A. M., and Weerts, Zsa Zsa R. M.
- Subjects
- *
TRPV cation channels , *ATROPHIC gastritis , *PRECANCEROUS conditions , *HELICOBACTER pylori , *INTESTINAL cancer , *GASTRIC mucosa - Abstract
The potential role of the transient receptor potential Vanilloid 1 (TRPV1) non-selective cation channel in gastric carcinogenesis remains unclear. The main objective of this study was to evaluate TRPV1 expression in gastric cancer (GC) and precursor lesions compared with controls. Patient inclusion was based on a retrospective review of pathology records. Patients were subdivided into five groups: Helicobacter pylori (H. pylori)-associated gastritis with gastric intestinal metaplasia (GIM) (n = 12), chronic atrophic gastritis (CAG) with GIM (n = 13), H. pylori-associated gastritis without GIM (n = 19), GC (n = 6) and controls (n = 5). TRPV1 expression was determined with immunohistochemistry and was significantly higher in patients with H. pylori-associated gastritis compared with controls (p = 0.002). TRPV1 expression was even higher in the presence of GIM compared with patients without GIM and controls (p < 0.001). There was a complete loss of TRPV1 expression in patients with GC. TRPV1 expression seems to contribute to gastric-mucosal inflammation and precursors of GC, which significantly increases in cancer precursor lesions but is completely lost in GC. These findings suggest TRPV1 expression to be a potential marker for precancerous conditions and a target for individualized treatment. Longitudinal studies are necessary to further address the role of TRPV1 in gastric carcinogenesis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. The toxic effects of Helicobacter pylori and benzo(a)pyrene in inducing atrophic gastritis and gut microbiota dysbiosis in Mongolian gerbils.
- Author
-
Huang, Yilun, Chen, Yunxiang, Ma, Lingfei, Guo, Honggang, Chen, Hao, Qiu, Bo, Yao, Mingfei, Huang, Weixin, and Zhu, Lian
- Subjects
- *
HELICOBACTER pylori , *BENZOPYRENE , *MONGOLIAN gerbil , *ATROPHIC gastritis , *POISONS , *GUT microbiome , *DYSBIOSIS - Abstract
Food chemical and microbiological contamination are major global food safety issues. This study investigated the combined effects of the food‐borne pathogen Helicobacter pylori (H. pylori) and the pollutant benzo(a)pyrene (Bap) on atrophic gastritis and gut microbiota in Mongolian gerbils. The results demonstrated that simultaneous administration of H. pylori and Bap caused more severe weight loss, DNA damage, and gastritis in Mongolian gerbils compared with those exposed to H. pylori or Bap alone. The combination also significantly increased the serum level of proinflammatory cytokines, including IL‐1β (p < .05), IL‐6 (p < .0001), and TNF‐α (p < .05). Additionally, the H. pylori and Bap combination altered the composition of gut microbiota in Mongolian gerbils: the relative abundance of Lactobacillus and Ligilactobacillus at the genus level (p < .05) was significantly reduced while the relative abundance of Allobaculum and Erysipelotrichaceae enhanced (p < .0001, p < .05). Our study revealed that the synergy of H. pylori and Bap can boost the development of atrophic gastritis and lead to gut microbiota dysbiosis in Mongolian gerbils, which provides essential implications for preventing contaminated foods to sustain life and promote well‐being. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. Development of a plasma maltose assay method as a screening test for upper gastrointestinal disorders.
- Author
-
Komene, Tetsuya, Kai, Kotoko, Kinpara, Kiyoko, Sato, Tomoaki, Hokazono, Eisaku, Shimosawa, Tatsuo, Osawa, Susumu, and Seimiya, Masanori
- Subjects
- *
BLOOD sugar , *ATROPHIC gastritis , *DISACCHARIDES , *BLOOD sampling , *MEDICAL screening - Abstract
Background and objective: The disaccharide loading test is a method to assess gastric mucosal damage. Since Trelan-G75, which is used for the sugar tolerance test, contains disaccharide maltose, if maltose is detected at a high sensitivity in the sample blood used in the sugar tolerance test, screening for upper gastrointestinal mucosal damage can be made simultaneously with the sugar tolerance test for the diagnosis of diabetes. Methods: Glucose-6-phosphate is generated by treating maltose with maltose phosphorylase, β-phosphoglucomutase, and glucose-1,6-bisphosphate. Then, change in the absorbance at 405 nm is measured by the enzymatic cycling method using Thio-NADP, β-NADPH, and Glucose-6-phosphate dehydrogenase. After evaluating the optimal condition for this method, it is mounted on an automatic biochemical analyzer, and samples after the sugar tolerance test were assayed. Results: Regarding the performance of this method, the repeatability was 10–50 μmol/L with a CV of ≤1.1%. Concerning the assay range, a curve passing the origin with a range of linearity up to 120 μmol/L was obtained. No effect of dyes or sugars in the blood was noted. As a result of application to patients with gastric mucosal disorders (those who had a health checkup), significant differences were observed depending on the stage of atrophic gastritis. Discussion: This method has a high sensitivity and a high precision and can be used for high-speed analysis on an automatic analyzer. It has the potential to be used as a screening test for gastric mucosal damage. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Endoscopic Grading and Sampling of Gastric Precancerous Lesions: A Comprehensive Literature Review.
- Author
-
Tziatzios, Georgios, Ziogas, Dimitrios Ι., Gkolfakis, Paraskevas, Papadopoulos, Vasilios, Papaefthymiou, Apostolis, Mathou, Nikoletta, Giannakopoulos, Athanasios, Gerasimatos, Gerasimos, Paraskeva, Konstantina D., and Triantafyllou, Konstantinos
- Subjects
- *
LITERATURE reviews , *PRECANCEROUS conditions , *GASTRIC mucosa , *DISEASE risk factors , *ENDOSCOPIC surgery , *ATROPHIC gastritis - Abstract
Gastric cancer remains a disease with an ominous prognosis, while early gastric cancer has a good-to-excellent prognosis, with 5-year survival rates of up to 92.6% after successful endoscopic resection. In this context, the accurate identification of patients with established gastric precancerous lesions, namely chronic atrophic gastritis and intestinal metaplasia, is the first step in a stepwise approach to minimize cancer risk. Although current guidelines advocate for the execution of random biopsies to stage the extent and severity of gastritis/intestinal metaplasia, modern biopsy protocols are still imperfect as they have limited reproducibility and are susceptible to sampling error. The advent of novel imaging-enhancing modalities, i.e., high-definition with virtual chromoendoscopy (CE), has revolutionized the inspection of gastric mucosa, leading to an endoscopy-based staging strategy for the management of these premalignant changes in the stomach. Nowadays, the incorporation of CE-targeted biopsies in everyday clinical practice offers not only the robust detection of premalignant lesions but also an improvement in quality, by reducing missed diagnoses along with mean biopsies and, thus, the procedural costs and the environmental footprint. In this review, we summarize the recent evidence regarding the endoscopic grading and sampling of gastric precancerous lesions. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
18. Characteristics of Helicobacter pylori Eradication Therapy in Patients 80 Years or Older Living in a Metropolitan Area: A Multicenter Retrospective Study.
- Author
-
Iwata, Eri, Sugimoto, Mitsushige, Asaoka, Daisuke, Hojo, Mariko, Ito, Masayoshi, Kitazawa, Naoko, Kurihara, Naoto, Masaoka, Tatsuhiro, Mizuno, Shigeaki, Mori, Hideki, Nagahara, Akihito, Niikura, Ryota, Ohkusa, Toshifumi, Sano, Masaya, Shimada, Yuji, Suzuki, Hidekazu, Takeuchi, Yoshiaki, Tanaka, Akifumi, Tokunaga, Kengo, and Ueda, Kumiko
- Subjects
- *
OLDER patients , *HELICOBACTER pylori , *ATROPHIC gastritis , *METROPOLITAN areas , *PEPTIC ulcer - Abstract
Background: The situation of Helicobacter pylori eradication therapy has been changing over time, owing to increases in antimicrobial‐resistant strains, lifestyle improvements, and changes in indications for eradication. In Japan, eradication therapy is now available to all H. pylori‐positive patients under the medical insurance system, and the potassium‐competitive acid blocker vonoprazan has been used for eradication from 2015. Recently, with the aging of society, opportunities to provide eradication to elderly patients are increasing, but the current status and effectiveness of eradication in elderly patients remains unclear. Therefore, we aimed to investigate the trends of H. pylori eradication in a metropolitan area to determine the factors associated with successful H. pylori eradication in elderly patients older than 80 years. Methods: Trends in the eradication rates of patients who received first‐ or second‐line eradication at 20 hospitals in the Tokyo metropolitan area from 2013 to 2023 were investigated. Results: The eradication rates in the per‐protocol analysis were 82.3% (95% confidence interval [CI]: 81.2%–83.2%) for the first‐line treatment (n = 6481), and 87.9% (86.9%–88.9%) for the second‐line treatment (n = 4899). Multivariate analysis showed that independent factors for successful eradication in the first‐line treatment were an age of older than 80 years (OR: 0.606; 95% CI: 0.448–0.822), peptic ulcers (vs. atrophic gastritis: 3.817; 3.286–4.433), and vonoprazan (vs. proton pump inhibiters (PPIs), 3.817; 3.286–4.433), and an age of older than 80 years (0.503; 0.362–0.699) and vonoprazan (1.386; 1.153–1.667) in the second‐line treatment. Conclusion: After 2015, the eradication rate of both first‐ and second‐line therapies were maintained at a higher level than before 2015, owing to the use of vonoprazan. As the H. pylori eradication rate in patients older than 80 years was low, an effective strategy for these patients needs to be developed in the future. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. Aplasia medular carencial por anemia perniciosa hereditaria.
- Author
-
Vargas Nieto, Lina Patricia, Estrada Maya, Juan P., Vargas Osorno, Manuela, and Medina Rincón, Germán J.
- Abstract
BACKGROUND: Vitamin B12 and both of its active forms, cyanocobalamin and hydroxycobalamin are essential micronutrients for cellular metabolism and division. Vitamin B12 is mostly obtained from animal-derived proteins, and its deficiency generates a systemic compromise with mainly neurologic and hematologic signs and symptoms. CLINICAL CASE: A 47-year-old male patient with positive family history for pernicious anemia and several other autoimmune affections presented to the Emergency department with medullary aplasia due to vitamin B12 deficiency. Diagnostic studies showed low levels of vitamin B12, a conclusive biopsy and positive anti-parietal cell antibodies confirmed pernicious anemia. Patient's symptoms were relieved with vitamin B12 supplementation. CONCLUSIONS: A genetic panel testing for AMN, CUBN, GIF, and holocortine mutations --all related to the vitamin B12 metabolic pathway--, as well as for the HLA-DRB1*03 and DRB1*04 haplotypes is suggested in young patients presenting with pernicious anemia and positive family history. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Reduction of Helicobacter pylori cells in rural water supply using slow sand filtration.
- Author
-
Leyton, Javier, Fernández, Javier, Acosta, Patricia, Quiroga, Andrés, and Codony, Francesc
- Subjects
HELICOBACTER pylori ,RURAL water supply ,DRINKING water quality ,SAND filtration (Water purification) ,WATER use ,DUODENAL ulcers ,ATROPHIC gastritis - Abstract
Helicobacter pylori is a microorganism that infects 60% of the population and is considered the main cause of atrophic gastritis, gastric and duodenal ulcers, and gastric cancer. Different emerging pathogens have been found in drinking water and their presence is considered to be an important public health problem. For this reason, it is necessary to carry out the validation of reliable technologies for this type of pathogens and evaluate their performance. This paper reports, for the first time, H. pylori reduction in a drinking water pilot plant of two slow sand filters (SSF). Inlet water was taken from a gravel filtration system of a rural water supply in Colombia and then inoculated with viable cells of H. pylori. By determining the Genomic Units (GU) through quantitative Polymerase Chain Reaction (qPCR), the concentration of GU/sample was measured. In the inlet water amplification for SSF1 and SSF2 were 5.13 × 10
2 ± 4.48 × 102 and 6.59 × 102 ± 7.32 × 102 , respectively, while for the treated water they were 7.0 ± 5.6 and 2.05 × 101 ± 2.9 × 101 GU/sample for SSF1 and SSF2, respectively. The SSF pilot plant reached up to 3 log reduction units of H. pylori; therefore, since there is not an H. pylori contamination indicator and its periodic monitoring is financially complicated, the SSF could guarantee the drinking water quality necessity that exists in rural areas and small municipalities in developing countries, where infection rates and prevalence of this pathogen are high. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
21. Validity of rapid urease test using swab of gastric mucus to mucosal forceps and 13 C-urease breath test: a multicenter prospective observational study
- Author
-
Takaaki Yoshikawa, Atsushi Yamauchi, Tadayuki Kou, Takahisa Murao, Tomoari Kamada, Mitsuhiko Suehiro, Koichiro Kawano, Ken Haruma, and Shujiro Yazumi
- Subjects
Helicobacter pylori ,Rapid urease test ,Atrophic gastritis ,13 C-urea breath test ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Abstract Background Theoretically, a rapid urease test (RUT) using a swab of the gastric wall (Swab-RUT) for Helicobacter pylori (H. pylori) is safe. However, the validity and utility of Swab-RUT remain unclear. Therefore, we assessed the validity and utility of Swab-RUT compared to RUT using mucosal forceps of the gastric wall (Forceps-RUT) and 13C-urea breath test (UBT). Methods This study was a multicenter prospective observational study. When the examinees were suspected of H. pylori infection during esophagogastroduodenoscopy, we performed Swab-RUT and Forceps-RUT continuously. When the examinees were not suspected of H. pylori infection, we performed Swab-RUT alone. We validated the status of H. pylori infection using UBT. Results Ninety-four examinees were enrolled from four institutions between May 2016 and December 2020 (median age [range], 56.5 [26–88] years). In this study, the sensitivity, specificity, and accuracy of Swab-RUT to UBT were 0.933 (95% confidence interval: 0.779–0.992), 0.922 (0.827–0.974), and 0.926 (0.853–0.970), respectively. The Kappa coefficient of Swab-RUT to UBT was 0.833, and that of Swab-RUT to forceps-RUT was 0.936. No complications were observed in this study. Conclusions Swab-RUT is a valid examination for the status of H. pylori infection compared to the conventional Forceps-RUT.
- Published
- 2024
- Full Text
- View/download PDF
22. A Study of Pre-Malignant Gastric Conditions
- Published
- 2023
23. Pepsinogen I, pepsinogen II, gastrin-17, and Helicobacter pylori serological biomarkers in the diagnosis of precursor lesions of gastric cancer
- Author
-
Josefina Yoaly Sánchez-López, Luis Carlos Díaz-Herrera, and Lourdes del Carmen Rizo-de la Torre
- Subjects
atrophic gastritis ,intestinal metaplasia ,gastric cancer ,helicobacter pylori ,biomarkers ,Medicine - Abstract
Introduction Atrophic gastritis and intestinal metaplasia are precursor lesions of gastric cancer. The aim of this study was to determine the usefulness of the biomarkers pepsinogen I(PgI), pepsinogen II (PgII), gastrin-17, and H. pylori antibodies in the identification of precursor lesions. Methods We studied 129 patients with gastric symptoms. The biomarker status was determined using GastroPanel by means of the ELISA-technique. Results Biomarkers detected atrophy in 14% of the subjects, and 49.6% had positive antibodies for H. pylori. A PgI/PgII ratio < 3 was an important risk biomarker for precursor lesions in our population (OR = 9.171, 95% CI: 1.723–48.799, p = 0.009); however, biomarkers showed low accuracy with histopathological study. Conclusions In the Western Mexican population, precursor lesions (AG, IM) are common in adults (45%) with dyspepsia but infrequent in children (8%). H. pylori infection was detected in 41.3% of adults and 16.0% of children. Of the studied biomarkers, a PgI/PgII ratio < 3 was an important risk factor for precursor lesions such as AG or IM in our population, with an OR of 9.171 (95% CI: 1.723–48.799, p = 0.009).
- Published
- 2024
- Full Text
- View/download PDF
24. Effect of Concomitant Use of Polaprezinc and Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication
- Author
-
Yuto Suzuki, Yasumi Katayama, Yo Fujimoto, Koji Toyoda, Morio Takahashi, and Masaya Tamano
- Subjects
polaprezinc ,vonoprazan ,Helicobacter pylori ,eradication ,atrophic gastritis ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Background: Vonoprazan-based triple therapy has recently been reported as being more effective than proton pump inhibitors for the eradication of Helicobacter pylori (H. pylori), but it is apparent that the eradication rate could be further improved. Methods: We investigated the effect of the concomitant use of polaprezinc, a therapeutic agent for gastric ulcers, and vonoprazan-based seven-day triple therapy in patients with gastric ulcers compared to standard vonoprazan-based seven-day triple therapy in patients with atrophic gastritis. The regimen for the treatment of atrophic gastritis contained vonoprazan 20 mg, amoxicillin 750 mg, and clarithromycin 200 mg b.d. (VAC group) for seven days; and that for gastric ulcers contained VAC and polaprezinc 75 mg b.d. (VACP group) for seven days. Results: Between October 2021 and January 2023, 201 subjects were examined (VAC group, n = 165; VACP group, n = 36). In per-protocol (PP) analysis, the eradication rate was significantly higher in the VACP group (100%) than in the VAC group (88.2%) (p = 0.025). In patients with severe atrophic gastritis, eradication rates were significantly higher in the VACP group (100%) than in the VAC group (84.4%) in PP analysis. (p = 0.024). Conclusions: The concomitant use of polaprezinc and standard vonoprazan-based first-line eradication therapy is effective for H. pylori.
- Published
- 2024
- Full Text
- View/download PDF
25. Detection Rate of Helicobacter Pylori Infection and Atrophic Gastritis Using Serological Markers 'GastroPanel®' Among Employees of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation
- Author
-
A. D. Kaprin, N. S. Sergeeva, S. S. Pirogov, I. I. Alentov, O. К. Yutsevich, V. I. Ryabtseva, G. F. Minibaeva, N. V. Marshutina, and T. А. Karmakova
- Subjects
gastropanel ,medical workers ,helicobacter pylori ,atrophic gastritis ,esophagogastroduodenoscopy ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Aim: to evaluate, using the “GastroPanel®”, the frequency of detection of H. pylori infection and associated gastric diseases among doctors and medical staff of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Moscow.Materials and methods. Employees of three branches of the National Medical Research Radiological Centre (n = 434, mean age — 48.5 ± 0.6 years) were examined using laboratory tests “GastroPanel®” (Biohit Oyj, Finland). The test results make it possible to identify infection of the stomach with H. pylori, hypo- and hyperacid conditions, as well as atrophic gastritis of the antrum and body of the stomach, as its precancerous conditions. Esophagogastroduodenoscopy (EGDS) for suspected atrophic gastritis was performed with an Olympus GIF-HQ190 video endoscope (Japan) in a narrow-spectrum mode with close focus (NBI Dual Focus).Results. The absence of pathological signs detected by “GastroPanel®” was established in 23.3 % of cases, hyperacid state — in 18.4 %, and hypoacid state — in 5.2 %. These disorders are classified as functional. Consequently, the conditional norm in total was identified in 46.9 % of observations. An increased level of antibodies to H. pylori was found in 43.3 % of those examined. Atrophic gastritis in the body of the stomach according to the results of the “GastroPanel®” was detected in 4.8 % of cases (median age — 59 years), in the antrum (or increased secretion of hydrochloric acid) — also in 4.8 % of cases (median age — 52 years). Within two months after laboratory diagnostics, EGDS was performed for 10 out of 15 patients examined at the P. Hertsen Moscow Oncology Research Institute in whom, based on the results of the “GastroPanel®”, the presence of atrophic gastritis in the antrum (or increased secretion of hydrochloric acid) was suspected. In 6 out of 10 cases, atrophic gastritis of the antrum was confirmed (in two of them, the atrophy extended to the body of the stomach and was assessed as severe). Of the 11 people with the “GastroPanel®” conclusion “Atrophic gastritis of the body of the stomach,” an endoscopic examination was carried out in 7 persons, and in all these cases the diagnosis was confirmed, and in two people the conclusion was made of severe atrophic pangastritis.Conclusion. “GastroPanel®” confirmed its high significance in identifying H. pylori infection and precancerous atrophic changes in the gastric mucosa. Regarding the occupational risks of infection among medical workers, we consider it advisable to conduct such screening without selecting an asymptomatic population.
- Published
- 2024
- Full Text
- View/download PDF
26. Intervention of astragaloside ? on chronic atrophic gastritis based on network pharmacology.
- Author
-
BAO Zhewei, HU Shunan, YANG Lanzhu, YU Wenjuan, and YANG Jingya
- Subjects
ATROPHIC gastritis ,GASTRIC mucosa ,PROTEIN-protein interactions ,MOLECULAR docking ,PHARMACOLOGY ,EPITHELIAL cells - Abstract
This study used network pharmacology to forecast and evaluate effectiveness in controlling chronic atrophic gastritis, laying the groundwork for its inclusion in functional foods. The target genes of astragaloside IV that control chronic atrophic gastritis were gathered for this experiment from databases such as Swiss Target Prediction, PharmaMapper, OMIM, etc. The target gene was identified by taking intersections. Based on the STRING database, a protein-protein interaction (PPI) network was created. Based on the centrality of the intermediate number, the PPI network did topology analysis using Cytoscape software, and simulated potential molecular docking outcome with Autodock Vina software. GO and KEGG enrichment analysis was conducted on the bioinformatics online platform to screen out relevant signal pathways. In vitro experiments were conducted by inducing GES-1 cells (human gastric mucosal epithelial cells) with MNNG (1-methyl- 3-nitro-1-nitrosoguanidine) and treating them with astragaloside IV to detect cell viability and inflammatory factor secretion levels for validation. Finally, 53 potential targets were identified for the regulation of chronic atrophic gastritis by astragaloside IV, including 8 key genes. GO enrichment analysis showed that the vesicular cavity was the main site for biological processes to occur. The KEGG results indicated that proteoglycans in tumors were a key signaling pathway for astragaloside IV to regulate chronic atrophic gastritis. In vitro experiments found that astragaloside IV had a preventive and therapeutic effect on MNNG-induced cell damage, and could downregulate IL-6, IL-8, IL-1β, and TNF-α (P < 0.05). This study showed that astragaloside IV could operate as a functional factor for the prevention and treatment of chronic atrophic gastritis and could exercise its anti-chronic atrophic gastritis impact through many targets and pathways. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
27. Non-Invasive Markers for the Detection of Gastric Precancerous Conditions.
- Author
-
Romańczyk, Marcin, Osmola, Malgorzata, Link, Alexander, Druet, Amaury, Hémont, Caroline, Martin, Jerome, Chapelle, Nicolas, and Matysiak-Budnik, Tamara
- Subjects
- *
PUBLIC health surveillance , *RISK assessment , *STOMACH tumors , *PRECANCEROUS conditions , *EARLY detection of cancer , *TUMOR markers , *ENZYMES , *METAPLASIA , *ATROPHIC gastritis , *ENDOSCOPIC gastrointestinal surgery , *EARLY diagnosis , *DISEASE risk factors - Abstract
Simple Summary: Individuals with atrophic gastritis and gastric intestinal metaplasia, considered gastric precancerous conditions (GPC), are at increased risk of developing gastric adenocarcinoma. The identification and surveillance of these patients are important for the diagnosis of early gastric neoplasia. Non-invasive markers of GPC with good diagnostic performance could allow the implementation of a stepwise screening approach and, with successful personalized endoscopic surveillance, possibly decrease gastric cancer morbidity and mortality. Pepsinogen I and II and their ratio are the most broadly investigated biomarkers with moderate diagnostic performance. Their combination with other markers like Helicobacter pylori antibodies and gastrin-17 (called GastroPanel®) allows for more precise identification of GPC but without significant improvement in overall performance. Other new serum biomarkers could possibly enhance the performance of pepsinogens. Some of them may be considered stand-alone biomarkers; however, until now, no high-quality data support the use of any of them. Gastric cancer (GC) is still one of the most prevalent cancers worldwide, with a high mortality rate, despite improvements in diagnostic and therapeutic strategies. To diminish the GC burden, a modification of the current diagnostic paradigm, and especially endoscopic diagnosis of symptomatic individuals, is necessary. In this review article, we present a broad review and the current knowledge status on serum biomarkers, including pepsinogens, gastrin, Gastropanel®, autoantibodies, and novel biomarkers, allowing us to estimate the risk of gastric precancerous conditions (GPC)—atrophic gastritis and gastric intestinal metaplasia. The aim of the article is to emphasize the role of non-invasive testing in GC prevention. This comprehensive review describes the pathophysiological background of investigated biomarkers, their status and performance based on available data, as well as their clinical applicability. We point out future perspectives of non-invasive testing and possible new biomarkers opportunities. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
28. Perspectives on the current pharmacological strategies for chronic and atrophic gastritis: can more be done?
- Author
-
Dilaghi, Emanuele, Carabotti, Marilia, and Annibale, Bruno
- Subjects
ATROPHIC gastritis ,PHARMACOLOGY ,PROTON pump inhibitors ,AUTOIMMUNE diseases ,DISEASE progression - Published
- 2024
- Full Text
- View/download PDF
29. Mutations in Helicobacter pylori infected patients with chronic gastritis, intestinal type of gastric cancer and familial gastric cancer.
- Author
-
Hnatyszyn, Andrzej, Szalata, Marlena, Zielińska, Aleksandra, Wielgus, Karolina, Danielewski, Mikołaj, Hnatyszyn, Piotr Tomasz, Pławski, Andrzej, Walkowiak, Jarosław, and Słomski, Ryszard
- Subjects
- *
HELICOBACTER pylori infections , *STOMACH cancer , *HELICOBACTER pylori , *INTESTINAL cancer , *GASTRITIS , *ATROPHIC gastritis - Abstract
Background: Development of sequential changes of mucous leading to gastric cancer and familial cases of gastric cancer of intestinal type is widely connected with Helicobacter pylori infections. In this study we analysed variants of genes involved in cancerogenesis and inflammatory processes of intestines in patients infected with H.pylori. Our goal was to test whether mutations in these genes predestinate to development of gastric cancer, and whether there is a genetic factor that makes it more likely for infections with H.pylori to cause gastric cancer. As infections with H. pylori are relatively common, discovering such genetic predispositions could be used for establishing risk-groups and for planning treatments. Methods: Our studies cover analysis of variants in genes involved in cancerogenesis: TP53 (rs11540652, rs587782329, COSM10771), MSH2 (rs193922376), MLH1 (rs63750217), and inflammatory processes of intestine: NOD2 (rs2066847, rs2066842), IL1A (rs1800587) and IL1B (rs1143634) from H.pylori-infected patients. Results: Mutations were more common in the group of patients with gastric cancer of intestinal type and familial cases of gastric cancer in comparison with patients with chronic gastritis, chronic atrophic gastritis, intestinal metaplasia, dysplasia or gastric cancer (p-value = 0.00824), with the prevalence of p53 mutations in patients with familial gastric cancer vs. patients with other changes of mucosa (p-value = 0.000049). Additionally, gastric cancer patients have mainly genotype TT or CT of the rs2066842 variant of the NOD2 gene. Conclusions: The lack of statistically significant changes of other interleukin genes involved in inflammatory processes may suggest the presence of H.pylori infection as a potential trigger for the development of the inflammatory process of the mucosa, leading through microbiota dysbiosis to the development of enteric gastric cancer. Mutations in analysed genes correlated with more severe mucosal changes, with a much more frequent presence of TP53 gene mutations, with a limited presence of other mutations in the familial history of gastric cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
30. Severe induction of aberrant DNA methylation by nodular gastritis in adults.
- Author
-
Sasaki, Akiko, Takeshima, Hideyuki, Yamashita, Satoshi, Ichita, Chikamasa, Kawachi, Jun, Naito, Wataru, Ohashi, Yui, Takeuchi, Chihiro, Fukuda, Masahide, Furuichi, Yumi, Yamamichi, Nobutake, Ando, Takayuki, Kobara, Hideki, Kotera, Tohru, Itoi, Takao, Sumida, Chihiro, Hamada, Akinobu, Koizumi, Kazuya, and Ushijima, Toshikazu
- Subjects
- *
DNA methylation , *TUMOR suppressor genes , *DNA demethylation , *OVARIAN follicle , *GASTRITIS , *ATROPHIC gastritis - Abstract
Background: Nodular gastritis (NG) is characterized by marked antral lymphoid follicle formation, and is a strong risk factor for diffuse-type gastric cancer in adults. However, it is unknown whether aberrant DNA methylation, which is induced by atrophic gastritis (AG) and is a risk for gastric cancer, is induced by NG. Here, we analyzed methylation induction by NG. Methods: Gastric mucosal samples were obtained from non-cancerous antral tissues of 16 NG and 20 AG patients with gastric cancer and 5 NG and 6 AG patients without, all age- and gender-matched. Genome-wide methylation analysis and expression analysis were conducted by a BeadChip array and RNA-sequencing, respectively. Results: Clustering analysis of non-cancerous antral tissues of NG and AG patients with gastric cancer was conducted using methylation levels of 585 promoter CpG islands (CGIs) of methylation-resistant genes, and a large fraction of NG samples formed a cluster with strong methylation induction. Promoter CGIs of CDH1 and DAPK1 tumor-suppressor genes were more methylated in NG than in AG. Notably, methylation levels of these genes were also higher in the antrum of NG patients without cancer. Genes related to lymphoid follicle formation, such as CXCL13/CXCR5 and CXCL12/CXCR4, had higher expression in NG, and genes involved in DNA demethylation TET2 and IDH1, had only half the expression in NG. Conclusions: Severe aberrant methylation, involving multiple tumor-suppressor genes, was induced in the gastric antrum and body of patients with NG, in accordance with their high gastric cancer risk. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
31. Effect of Concomitant Use of Polaprezinc and Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication.
- Author
-
Suzuki, Yuto, Katayama, Yasumi, Fujimoto, Yo, Toyoda, Koji, Takahashi, Morio, and Tamano, Masaya
- Subjects
- *
HELICOBACTER pylori , *ATROPHIC gastritis , *STOMACH ulcers , *PROTON pump inhibitors - Abstract
Background: Vonoprazan-based triple therapy has recently been reported as being more effective than proton pump inhibitors for the eradication of Helicobacter pylori (H. pylori), but it is apparent that the eradication rate could be further improved. Methods: We investigated the effect of the concomitant use of polaprezinc, a therapeutic agent for gastric ulcers, and vonoprazan-based seven-day triple therapy in patients with gastric ulcers compared to standard vonoprazan-based seven-day triple therapy in patients with atrophic gastritis. The regimen for the treatment of atrophic gastritis contained vonoprazan 20 mg, amoxicillin 750 mg, and clarithromycin 200 mg b.d. (VAC group) for seven days; and that for gastric ulcers contained VAC and polaprezinc 75 mg b.d. (VACP group) for seven days. Results: Between October 2021 and January 2023, 201 subjects were examined (VAC group, n = 165; VACP group, n = 36). In per-protocol (PP) analysis, the eradication rate was significantly higher in the VACP group (100%) than in the VAC group (88.2%) (p = 0.025). In patients with severe atrophic gastritis, eradication rates were significantly higher in the VACP group (100%) than in the VAC group (84.4%) in PP analysis. (p = 0.024). Conclusions: The concomitant use of polaprezinc and standard vonoprazan-based first-line eradication therapy is effective for H. pylori. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
32. Pepsinogen I, pepsinogen II, gastrin-17, and Helicobacter pylori serological biomarkers in the diagnosis of precursor lesions of gastric cancer.
- Author
-
Yoaly Sánchez-López, Josefina, Carlos Díaz-Herrera, Luis, and Rizo-de la Torre, Lourdes del Carmen
- Subjects
- *
PEPSINOGEN , *STOMACH cancer , *HELICOBACTER pylori , *HELICOBACTER pylori infections , *BIOMARKERS , *ATROPHIC gastritis - Abstract
Introduction: Atrophic gastritis and intestinal metaplasia are precursor lesions of gastric cancer. The aim of this study was to determine the usefulness of the biomarkers pepsinogen I(PgI), pepsinogen II (PgII), gastrin-17, and H. pylori antibodies in the identification of precursor lesions. Methods: We studied 129 patients with gastric symptoms. The biomarker status was determined using GastroPanel by means of the ELISA-technique. Results: Biomarkers detected atrophy in 14% of the subjects, and 49.6% had positive antibodies for H. pylori. A PgI/PgII ratio < 3 was an important risk biomarker for precursor lesions in our population (OR = 9.171, 95% CI: 1.723-48.799, p = 0.009); however, biomarkers showed low accuracy with histopathological study. Conclusions: In the Western Mexican population, precursor lesions (AG, IM) are common in adults (45%) with dyspepsia but infrequent in children (8%). H. pylori infection was detected in 41.3% of adults and 16.0% of children. Of the studied biomarkers, a PgI/PgII ratio < 3 was an important risk factor for precursor lesions such as AG or IM in our population, with an OR of 9.171 (95% CI: 1.723-48.799, p = 0.009). [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
33. Survey on the Knowledge and the Management of Helicobacter pylori Infection by Italian General Practitioners and Doctors in General Practice Training.
- Author
-
Tosetti, Cesare, Ubaldi, Enzo, Benedetto, Edoardo, Bertolusso, Luciano, Napoli, Luigi, Cottone, Carmelo, Scoglio, Riccardo, Belvedere, Alessandra, Casella, Giovanni, Mancuso, Maurizio, Abagnale, Gennaro, Sanna, Guido, and De Bastiani, Rudi
- Subjects
HELICOBACTER disease treatment ,HELICOBACTER disease diagnosis ,MEDICAL protocols ,IRON deficiency anemia ,FAMILY medicine ,PRIMARY health care ,QUESTIONNAIRES ,DESCRIPTIVE statistics ,CHI-squared test ,MANN Whitney U Test ,SURVEYS ,PROFESSIONS ,INDIGESTION ,QUINOLONE antibacterial agents ,ATROPHIC gastritis ,DATA analysis software - Abstract
The management of gastric Helicobacter pylori (H. pylori) infection represents a significant concern in primary healthcare. This survey evaluates the approaches, attitudes, and knowledge regarding gastric H. pylori infection among Italian general practitioners (GPs) and young doctors undergoing general practice training (ITGPs). The survey enrolled 466 GPs and 70 ITGPs. Among GPs, specialist recommendations and the Maastricht–Florence guidelines were frequently referenced sources, while ITGPs relied more on the Maastricht–Florence guidelines and internet resources. ITGPs demonstrated more proactive approaches than GPs in investigating and treating conditions such as gastric ulcers, atrophic gastritis, and iron-deficiency anemia. However, there was limited attention given to the role of H. pylori treatment in first-degree relatives of gastric cancer patients. The most used diagnostic methods were the urea breath test and fecal test. Triple therapy was the most frequently chosen initial treatment regimen, with quadruple bismuth therapy becoming the primary option after initial treatment failure, followed by quinolone therapy and concomitant therapy. This survey underscores a disparity between real-world practices and the recommendations outlined in current guidelines, indicating a need for improved understanding of H. pylori guidelines among both GPs and ITGPs. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
34. Pathogenesis and potential reversibility of intestinal metaplasia − a milestone in gastric carcinogenesis.
- Author
-
Drnovsek, Jan, Homan, Matjaz, Zidar, Nina, and Smid, Lojze M
- Subjects
RISK assessment ,STOMACH tumors ,CANCER relapse ,EPIGENOMICS ,PRECANCEROUS conditions ,METAPLASIA ,GASTRIC mucosa ,INTESTINAL tumors ,HELICOBACTER diseases ,ATROPHIC gastritis ,INFLAMMATION ,DISEASE risk factors ,DISEASE complications - Abstract
Non-cardia gastric cancer remains a major cause of cancer-related mortality worldwide, despite declining incidence rates in many industrialized countries. The development of intestinal-type gastric cancer occurs through a multistep process in which normal mucosa is sequentially transformed into hyperproliferative epithelium, followed by metaplastic processes leading to carcinogenesis. Chronic infection with Helicobacter pylori is the primary etiological agent that causes chronic inflammation of the gastric mucosa, induces atrophic gastritis, and can lead to intestinal metaplasia and dysplasia. Both intestinal metaplasia and dysplasia are precancerous lesions, in which gastric cancer is more likely to occur. Atrophic gastritis often improves after eradication of Helicobacter pylori; however, the occurrence of intestinal metaplasia has been traditionally regarded as "the point of no return" in the carcinogenesis sequence. Helicobacter pylori eradication heals non-atrophic chronic gastritis, may lead to regression of atrophic gastritis, and reduces the risk of gastric cancer in patients with these conditions. In this article, we discuss the pathogenesis, epigenomics, and reversibility of intestinal metaplasia and briefly touch upon potential treatment strategy. Gastric intestinal metaplasia no longer appears to be an irreversible precancerous lesion. However, there are still many controversies regarding the improvement of intestinal metaplasia after Helicobacter pylori eradication. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
35. Vitamin B12 Status and Supplementation in Plant-Based Diets.
- Author
-
Hannibal, Luciana, Lederer, Ann-Kathrin, Storz, Maximilian A., Huber, Roman, and Jacobsen, Donald W.
- Subjects
PLANT-based diet ,DIETARY supplements ,VITAMINS ,TYPE 2 diabetes ,ATROPHIC gastritis - Abstract
Plant-based diets are increasingly popular worldwide. A well-planned plant-based diet lowers the risk of cardiovascular disease, type 2 diabetes and certain cancers. In contrast, a poorly planned plant-based diet increases the risk of certain micronutrient deficiencies, chiefly, vitamin B
12 (B12 ). Because B12 is not present in plants or in unfortified plant-based foodstuffs, the safest way to prevent its deficiency in plant-based diets is to take an oral B12 supplement. Studies determining the dose and frequency of B12 to be taken by healthy individuals on a plant-based diet to support an adequate B12 status are scarce. Here, we summarize the natural sources, metabolic requirements, biomarker findings with and without supplementation with B12 , and current recommendations to help prevent vitamin B12 deficiency in healthy individuals adhering or transitioning to plant-based diets. This review focuses on the prevention of vitamin B12 deficiency in healthy individuals adhering to plant-based diets. The information covered in this review does not apply to individuals suffering from autoimmune-based malabsorption of vitamin B12 resulting from pernicious anemia due to atrophic gastritis, other acquired causes of B12 malabsorption or to those with genetic disorders that impair vitamin B12 absorption, transport and utilization. Plain language title: Vitamin B12 in Plant-Based Diets Plain language summary: Plant-based diets are increasingly popular worldwide. Because vitamin B12 is not found in plants, individuals must acquire the micronutrient by consuming fortified foods or by taking an oral vitamin B12 supplement. We review B12 sources, required daily intake, and use of B12 supplements among those on plant-based diets. The safest way to prevent B12 deficiency in individuals adhering to plant-based diets is by using an oral B12 supplement. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
36. Non-invasive Testing in Gastric Diseases.
- Author
-
Leja, Mārcis
- Abstract
Purpose of Review: Non-invasive markers for gastric disease are highly useful, ideally allowing to diagnose a disease or a condition in a simple and convenient way. Such markers could also be of importance in population-based screening. Recent Findings: This review provides an overview of non-invasive markers for H.pylori gastritis, autoimmune gastritis, gastric precancerous conditions and lesions, as well as gastric cancer. Traditionally used markers, such as non-invasive tests for H.pylori, pepsinogen and gastrin tests for atrophic gastritis, anti-parietal cell and anti- intrinsic factor antibodies for autoimmune gastritis, as well as newer tests are discussed. Current key guidelines on the routinely used tests are summarized. A brief insight is provided to the status of volatile breath markers, plasma metabolic fingerprinting, as well as the use of circulating tumor cells, circulating tumor DNA, cell-free RNA, and extracellular vesicles in gastric cancer testing. Summary: There is still a clear unmet need for perfect non-invasive markers in early gastric cancer and precancer lesion detection. Additional research is required to justify the available test application in clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
37. Gastric intestinal metaplasia: Prevalence in a large Australian center and nationwide survey of endoscopic practice.
- Author
-
Hartley, Imogen, Connoley, Declan, Sane, Nikhita, Hirsch, Ryan, Abeywickrama, Dilini, Sim, Nicholle, Ea, Vinny, Azzopardi, Robert, Simpson, Ian, Bell, Sally, and Hew, Simon
- Subjects
METAPLASIA ,INTESTINES ,DYSPLASIA ,GASTROSCOPY - Abstract
Background and Aim: Atrophic gastritis (AG) and gastric intestinal metaplasia (GIM) are early changes in the stepwise progression to gastric adenocarcinoma. There is heterogeneity in international guidelines regarding the endoscopic diagnosis and surveillance of AG and GIM. This study aims to determine the prevalence of GIM in an Australian center and assess the approach of Australian endoscopists for these two conditions. Methods: We conducted a single‐center retrospective study of adult patients between January 2015 and December 2020 diagnosed with GIM on gastric biopsy following upper gastric endoscopy. A web‐based, 25‐question, investigator‐designed, multiple‐choice survey was distributed among all registered endoscopists in Australia. Results: The overall prevalence of GIM within a single Australian center was 11.7% over 5 years. Of the 1026 patients identified, only 58.7% underwent mapping biopsies using the modified Sydney protocol. Among the cohort, 1.6% had low‐grade dysplasia, 0.9% had high‐grade dysplasia, and 1.8% had malignancy on initial gastroscopy. Two hundred and sixty‐seven (7.2%) endoscopists completed the survey, 44.2% indicated they would perform mapping for all patients, and 36% only for high‐risk patients. Only 1.5% (n = 4) of respondents were able to correctly identify all six endoscopic photos of GIM/AG. Conclusion: This study demonstrates that in a large tertiary center, GIM is a prevalent endoscopic finding, but the associated rates of dysplasia and cancer were low. Additionally, among a small proportion of surveyed Australian endoscopists, there is notable variability in the endoscopic approach for AG and GIM and significant knowledge gaps. More training is required to increase the recognition of GIM and compliance with histological mapping. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
38. A Natural Peptide from A Traditional Chinese Medicine Has the Potential to Treat Chronic Atrophic Gastritis by Activating Gastric Stem Cells.
- Author
-
Li, Ke, Ma, Xiuying, Li, Zihao, Liu, Ya, Shen, Guiyan, Luo, Zecheng, Wang, Dong, Xia, Li, Wang, Zhengting, Tian, Ming, Liu, Huijuan, Geng, Funeng, and Li, Baojie
- Subjects
- *
CHINESE medicine , *ATROPHIC gastritis , *PEPTIDES , *STEM cells , *HELICOBACTER pylori infections , *GASTRIC mucosa - Abstract
Chronic atrophic gastritis (AG) is initiated mainly by Helicobacter pylori infection, which may progress to stomach cancer following the Correa's cascade. The current treatment regimen is H. pylori eradication, yet evidence is lacking that this treatment is effective on later stages of AG especially gastric gland atrophy. Here, using AG mouse model, patient samples, gastric organoids, and lineage tracing, this study unraveled gastric stem cell (GSC) defect as a crucial pathogenic factor in AG in mouse and human. Moreover, a natural peptide is isolated from a traditional Chinese medicine that activated GSCs to regenerate gastric epithelia in experimental AG models and revitalized the atrophic gastric organoids derived from patients. It is further shown that the peptide exerts its functions by stabilizing the EGF‐EGFR complex and specifically activating the downstream ERK and Stat1 signaling. Overall, these findings advance the understanding of AG pathogenesis and open a new avenue for AG treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
39. Frequency of Clinically Significant Findings in the Surgical Pathology Specimen Following Laparoscopic Sleeve Gastrectomy and Concordance with Preoperative Endoscopy: Insights from a Large Single-Center Experience.
- Author
-
Owen, Christopher K., Felinski, Melissa M., Bajwa, Kulvinder S., Walker, Peter A., Mehta, Sheilendra S., Wilson, Erik B., Boodoo, Stefanie, Kudav, Vishal, Akhtar, Shaan J., Shah, Shinil K., and Kling, M. Elaine
- Subjects
SLEEVE gastrectomy ,SURGICAL pathology ,ENDOSCOPIC surgery ,GASTRIC bypass ,ENDOSCOPY ,GASTROINTESTINAL stromal tumors - Abstract
Introduction: Endoscopy prior to bariatric surgery is not always performed, and in sleeve gastrectomy (SG), the surgical specimen is not always sent for pathological examination. There is limited data on the frequency of clinically significant findings in SG specimens or correlation with preoperative endoscopy. Methods: We reviewed 426 consecutive SG patients to determine the concordance of preoperative endoscopy findings in patients with clinically significant postoperative pathology. Results: Preoperative endoscopy was performed on 397 patients (93.2%). Three hundred seventy-three patients had preoperative endoscopy and surgical pathology results available. Then, 20/373 (5.4%) patients had potentially significant postoperative pathology, including intestinal metaplasia, autoimmune metaplastic atrophic gastritis (AMAG), gastrointestinal stromal tumors, and/or gastric cancer. The overall incidence of AMAG in the entire cohort was 2.3%. Preoperative gastric biopsies (to include gastric body) identified AMAG in nearly 1/2 of patients. Patients with clinically significant postoperative pathology results had a median [interquartile range] of 3 [3–5] tissue blocks examined as compared to 3 [1–3] for the remainder of the cohort (p < 0.001). Conclusion: This is one of the largest studies describing clinically significant postoperative pathology after SG. AMAG, in particular, is of particular importance as it is associated with a 3–fivefold increase in risk for gastric cancer. The incidence of significant postoperative pathology in this population is small but potentially clinically significant and requires validation in larger studies. We recommend wider sampling in preoperative endoscopy (body and antrum), especially in patients being planned for gastric bypass, consideration for routine pathological examination of SG surgical specimens, with careful gross examination and targeted sampling. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
40. Clinicopathologic and endoscopic characteristics of ten patients with gastric hamartomatous inverted polyp: a single center case series.
- Author
-
Dong, Ningning, Meng, Fandong, Yue, Bing, and Hou, Junzhen
- Subjects
- *
HELICOBACTER pylori infections , *CLINICAL pathology , *GASTRIC mucosa , *ATROPHIC gastritis , *ENDOSCOPIC ultrasonography , *PRECANCEROUS conditions - Abstract
Background: Gastric hamartomatous inverted polyps (GHIPs) are not well characterized and remain diagnostically challenging due to rarity. Therefore, this study aims to investigate the clinicopathologic and endoscopic characteristics of patients with GHIP. Methods: We retrospectively reviewed clinicopathologic and endoscopic features of ten patients with GHIP who were admitted to Beijing Friendship Hospital from March 2013 to July 2022. All patients were treated successfully by endoscopic resection. Results: GHIPs were usually asymptomatic and found incidentally during gastroscopic examination. They may be sessile or pedunculated, with diffuse or local surface redness or erosion. On endoscopic ultrasonography, the sessile submucosal tumor-type GHIP demonstrated a heterogeneous lesion with cystic areas in the third layer of the gastric wall. Histologically, GHIPs were characterized by a submucosal inverted proliferation of cystically dilated hyperplastic gastric glands accompanied by a branching proliferation of smooth muscle bundles. Inflammatory cells infiltration was observed in the stroma, whereas only one patient was complicated with glandular low-grade dysplasia. Assessment of the surrounding mucosa demonstrated that six patients (60%) had atrophic gastritis or Helicobacter pylori–associated gastritis, and four patients (40%) had non-specific gastritis. Endoscopic resection was safe and effective. Conclusions: GHIPs often arise from the background of abnormal mucosa, such as atrophic or H.pylori-associated gastritis. We make the hypothesis that acquired inflammation might lead to the development of GHIPs. We recommend to make a full assessment of the background mucosa and H. pylori infection status for evaluation of underlying gastric mucosal abnormalities, which may be the preneoplastic condition of the stomach. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
41. Gastric intestinal metaplasia: progress and remaining challenges.
- Author
-
Tong, Qi-Yue, Pang, Min-Jiao, Hu, Xiao-Hai, Huang, Xuan-Zhang, Sun, Jing-Xu, Wang, Xin-Yu, Burclaff, Joseph, Mills, Jason C., Wang, Zhen-Ning, and Miao, Zhi-Feng
- Subjects
- *
METAPLASIA , *PARIETAL cells , *GASTRIC diseases , *INTESTINES , *STOMACH cancer , *CANCER cell differentiation , *ATROPHIC gastritis - Abstract
Most gastric cancers arise in the setting of chronic inflammation which alters gland organization, such that acid-pumping parietal cells are lost, and remaining cells undergo metaplastic change in differentiation patterns. From a basic science perspective, recent progress has been made in understanding how atrophy and initial pyloric metaplasia occur. However, pathologists and cancer biologists have long been focused on the development of intestinal metaplasia patterns in this setting. Arguably, much less progress has been made in understanding the mechanisms that lead to the intestinalization seen in chronic atrophic gastritis and pyloric metaplasia. One plausible explanation for this disparity lies in the notable absence of reliable and reproducible small animal models within the field, which would facilitate the investigation of the mechanisms underlying the development of gastric intestinal metaplasia (GIM). This review offers an in-depth exploration of the current state of research in GIM, shedding light on its pivotal role in tumorigenesis. We delve into the histological subtypes of GIM and explore their respective associations with tumor formation. We present the current repertoire of biomarkers utilized to delineate the origins and progression of GIM and provide a comprehensive survey of the available, albeit limited, mouse lines employed for modeling GIM and engage in a discussion regarding potential cell lineages that serve as the origins of GIM. Finally, we expound upon the myriad signaling pathways recognized for their activity in GIM and posit on their potential overlap and interactions that contribute to the ultimate manifestation of the disease phenotype. Through our exhaustive review of the progression from gastric disease to GIM, we aim to establish the groundwork for future research endeavors dedicated to elucidating the etiology of GIM and developing strategies for its prevention and treatment, considering its potential precancerous nature. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
42. Autoimmune Atrophic Gastritis: A Clinical Review.
- Author
-
Castellana, Chiara, Eusebi, Leonardo Henry, Dajti, Elton, Iascone, Veronica, Vestito, Amanda, Fusaroli, Pietro, Fuccio, Lorenzo, D'Errico, Antonietta, and Zagari, Rocco Maurizio
- Subjects
- *
TUMOR risk factors , *AUTOIMMUNE disease treatment , *AUTOIMMUNE disease diagnosis , *PUBLIC health surveillance , *IRON , *IRON in the body , *STOMACH tumors , *ENDOSCOPIC surgery , *VITAMIN B12 , *GASTRIC mucosa , *AUTOIMMUNE diseases , *ATROPHIC gastritis , *NEUROENDOCRINE tumors , *ENDOSCOPY , *DISEASE risk factors - Abstract
Simple Summary: Autoimmune atrophic gastritis can lead to serious conditions, including malabsorption and vitamin deficiencies, that may cause anemia, neurological disorders, and gastric malignancies. This paper provides recent evidence on the pathogenesis, diagnosis, clinical presentation, risk of malignancies, endoscopic surveillance, and treatment of autoimmune atrophic gastritis. This review provides a valuable update for healthcare professionals and researchers, and the findings may help improve the diagnosis and management of patients with autoimmune atrophic gastritis, leading to improved outcomes and shaping future research directions. Autoimmune atrophic gastritis (AAG) is a chronic condition characterized by the presence of atrophy in the oxyntic mucosa due to anti-parietal cell antibodies. This review provides a comprehensive and up-to-date overview of autoimmune atrophic gastritis, reporting recent evidence on epidemiology, pathogenesis, diagnosis, clinical presentation, risk of malignancies, and management. The prevalence of AAG has been estimated at between 0.3% and 2.7% in the general population. The diagnosis of AAG is based on a combination of the serologic profile and the histological examination of gastric biopsies. Patients with AAG are often asymptomatic but can also have dyspeptic or reflux symptoms. The atrophy of the oxyntic mucosa leads to iron and vitamin B12 malabsorption, which may result in anemia and neurological affections. Autoimmune atrophic gastritis is associated with an increased risk of type I neuroendocrine tumors (NETs) and gastric cancer, with an incidence rate of 2.8% and 0.5% per person/year, respectively. Management is directed to reinstate vitamins and iron and to prevent malignancies with endoscopic surveillance. In conclusion, atrophic autoimmune gastritis is an infrequent condition, often asymptomatic and misdiagnosed, that requires an early diagnosis for appropriate vitamin supplementation and endoscopic follow-up for the early diagnosis of NETs and gastric cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
43. Iron deficiency in pernicious anemia: Specific features of iron deficient patients and preliminary data on response to iron supplementation.
- Author
-
Rogez, Juliette, Urbanski, Geoffrey, Vinatier, Emeline, Lavigne, Christian, Emmanuel, Léa, Dupin, Iris, Ravaiau, Camille, and Lacombe, Valentin
- Abstract
While vitamin B12 (B12) deficiency is considered as the hallmark of pernicious anemia (PA), iron deficiency (ID) is also prevalent. Indeed, this auto immune gastritis is responsible for parietal cell atrophy and increase in gastric pH, leading to impaired iron absorption. We compared PA patients' features according to their iron status at PA diagnosis, and we assessed the iron status recovery after oral or intravenous iron supplementation. We prospectively included patients presenting with a newly diagnosed PA in a tertiary referral hospital between November 2018 and October 2020. Iron status was assessed at PA diagnosis then regularly during a standardized follow-up. In case of ID, the decision of treatment with oral and/or intravenous iron supplementation was left to the clinician convenience. We included 28 patients with newly diagnosed PA. ID was observed in 21/28 (75.0%) patients: from the PA diagnosis in 13 patients, or during the follow-up in 8 patients. Iron deficient PA patients had higher plasma B12 (p = 0.04) and lower homocysteine levels (p = 0.04). Also, ID was independently associated with the 'APCA (anti-parietal cell antibodies) alone' immunological status (absence of anti-intrinsic factor antibodies) after adjustment for age, gender and B12 level (aOR 12.1 [1.1–141.8], p = 0.04). High level of APCA was associated with lower ferritin level. After 3 months of supplementation, 3/11 PA patients normalized the iron status with oral iron supplementation, versus 7/8 with intravenous iron supplementation (p = 0.02). The high frequency of iron deficiency in PA highlights the interest of regular assessment of iron status in this condition. ID was associated with a profile including APCA alone and less pronounced B12 deficiency. Intravenous iron supplementation seemed to be more efficient than an oral supplementation in these preliminary data. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
44. Gastric Mucosal Changes and Frequency of Helicobacter pylori in Patients with Gastroenterostomy.
- Author
-
Sezer, Semih and Ödemiş, Bülent
- Subjects
HELICOBACTER pylori infections ,GASTRIC mucosa ,GASTROENTEROSTOMY ,ATROPHIC gastritis ,DISEASE incidence - Abstract
Objective: We investigated endoscopic and pathological changes in the gastric mucosa and the frequency of Helicobacter pylori (Hp) infection in patients undergoing gastroenterostomy surgery. Materials and Methods: Patients who were admitted to our hospital between November 2009 and April 2010 and who had previously undergone gastroenterostomy surgery for any reason were included in the study. The control group consisted of patients without gastroenterostomy who underwent routine endoscopy. Results: Hp was positive in 10 of 70 patients with gastroenterostomy (14.3%) and in 30 of 50 patients (60%) in the control group. The difference between the two groups was statistically significant (p<0.001). Intestinal metaplasia was detected in 22 of 70 patients (31.4%) and in 8 of 50 patients (16%) in the gastroenterostmy and control groups, respectively (p=0.054). Atrophic gastritis was detected in 42 of 70 patients (60%) and in 15 of 50 patients (30%). The difference was statistically significant (p<0.01). Dysplasia and adenocarcinoma were detected in 4 (5.5%) patients (dysplasia in 1 patient, adenocarcinoma in 3 patients) in the gastroenterostomy group, but not in the control group (p<0.02). Conclusion: This study showed that the frequency of enterogastric reflux increased in patients who underwent gastroenterostomy and correspondingly decreased Hp's frequency. The incidence of atrophic gastritis and dysplasia from precancerous gastric lesions is significantly higher in patients who undergo gastroenterostomy. In light of these results, because enterogastric reflux and Hp have a synergistic damage effect on the gastric mucosa, we recommend that patients with gastroenterostomy should be tested for Hp, and if positive, they should be eradicated, and biopsies should be taken from the distal remnant gastric mucosa close to the stoma line. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
45. The investigation of B12 deficiency leading to the serendipitous diagnosis of gastric carcinoid tumour
- Author
-
Karam Karam, Sarah Saleh, Houssein Chebbo, Sarah Jalloul, and Elias Fiani
- Subjects
gastric net ,atrophic gastritis ,pernicious anaemia ,Medicine - Abstract
Gastric carcinoid is a rare type of gastric malignancy accounting for around 7% of all gastrointestinal neuroendocrine tumours (NETs). While most gastric NETs (gNETs) are readily visible through direct visualisation by upper endoscopy, around 25% of gastric carcinoids are invisible because they are located in the submucosal gastric regions of the body and fundus. gNETs located in the intra-mucosal areas can be identified by gastric mapping; this can be done by taking random gastric biopsies from the antrum, body and fundus. We report a case of a well-differentiated gastric NET type 1 with atrophic gastritis diagnosed on upper endoscopy and pathological immunohistochemistry staining.
- Published
- 2024
- Full Text
- View/download PDF
46. Streptococcus anginosus: A new pathogen of superficial gastritis, atrophic gastritis and gastric cancer
- Author
-
Fengting Guo, Lanfang Li, and Lifang Li
- Subjects
Atrophic gastritis ,gastric cancer ,Helicobacter pylori ,Streptococcus anginosus ,superficial gastritis ,Biology (General) ,QH301-705.5 - Abstract
A wealth of research indicates that superficial gastritis (SG) and atrophic gastritis (AG) are precursors to gastric cancer (GC). While Helicobacter pylori (H. pylori) has long been recognized as a key player in GC development, recent findings by Fu et al. have identified Streptococcus anginosus (S. anginosus) as an emerging pathogen that can trigger SG, AG and GC. S. anginosus, a gram-positive coccus, leverages its surface protein T. pallidum membrane protein C (TMPC) to engage with the annexin A2 (ANXA2) receptor of gastric epithelial cells, facilitating its colonization and invasion in the gastric mucosa. This leads to an upregulation of proinflammatory chemokines Ccl20 and Ccl8, causing prolonged effects on gastric barrier function and microbiota homeostasis, leading to SG. Moreover, these bacteria activate the mitogen-activated protein kinase (MAPK) signaling pathway, which is associated with the development of AG and GC. Importantly, inhibiting TMPC or knocking down ANXA2 can reduce S. anginosus colonization and invasion, lowering the chances of SG, AG, and GC. This paper highlights the molecular mechanisms of S. anginosus in SG, AG and GC, emphasizing the importance of a multi-pathogen strategy in gastric disease management and the need for further investigation into the role of S. anginosus in GC progression.
- Published
- 2024
- Full Text
- View/download PDF
47. AG & IM in CA Stomach Protocol
- Author
-
Hon Chi Yip, Associate Consultant
- Published
- 2023
48. Endoscopic Surveillance on a High-risk Population for Gastric Cancer in Latin America: The ECHOS Cohort Study. (ECHOS)
- Author
-
Agencia Nacional de Investigación y Desarrollo and European Union
- Published
- 2023
49. Analysis of Helicobacter pylori resistance in patients with different gastric diseases
- Author
-
Yongfu Shao, Yifan Lin, Ziyi Fang, Jianing Yan, Tuo Zheng, and Guoliang Ye
- Subjects
Helicobacter pylori ,Antibiotic resistance ,Antimicrobial susceptibility test ,Atrophic gastritis ,Proton pump inhibitor ,Medicine ,Science - Abstract
Abstract Helicobacter pylori (H. pylori) resistance is the most important risk factor for eradication failure. However, in most regions, antibiotic resistance rates of H. pylori in patients with different types of gastric mucosal lesions are still unclear. An 8-year clinical retrospective cohort study involving 2847 patients was performed. In this study, we first summarized and compared the resistance status of H. pylori in different years, ages, sexes, and gastric diseases. The resistance profiles of amoxicillin (AMX), clarithromycin (CLR), levofloxacin (LVX) and furazolidone (FR) and their changing trends in the clinic were described. Then, multiple antibiotic resistance in different gastric diseases and years were described and compared. The relationship between proton pump inhibitor (PPI) medication history and antibiotic resistance in H. pylori was also explored. Finally, an antibiotic resistance risk model was constructed for clinical resistance risk prediction. The overall resistance rates of AMX, CLR, LVX and FR in gastric diseases were 8.18%, 38.11%, 43.98%, and 13.73%, respectively. The mono resistance, double resistance, triple resistance, and quadruple resistance rates were 30.17%, 25.96%, 6.46%, and 0.63%, respectively. Compared with the period from 2014 to 2016, the rates of mono-resistance and multiple resistance all showed relatively downward trends in the past 5 years. Factors including age, sex, type of gastric lesions and recent PPI treatment history are associated with the antibiotic resistance rate of H. pylori. Atrophic gastritis is an important clinical feature of high-risk antibiotic resistance in H. pylori-infected patients. Patients with atrophic gastritis have higher risk of resistant strains infection. In this study, our data provide the association between antibiotic resistance of H. pylori and gastritis pattern, which indicate the higher risk of resistant strain infection if the patients with atrophic gastritis, PPI history and older age.
- Published
- 2024
- Full Text
- View/download PDF
50. Utilization of an Automated Latex Agglutination Turbidity Assay for Assessing Gastric Mucosal Alteration during Helicobacter pylori Infection
- Author
-
Ayush Khangai, Junko Akada, Batsaikhan Saruuljavkhlan, Boldbaatar Gantuya, Dashdorj Azzaya, Khasag Oyuntsetseg, Duger Davaadorj, Tomohisa Uchida, Takashi Matsumoto, and Yoshio Yamaoka
- Subjects
helicobacter pylori ,latex agglutination test ,e-plate ,atrophic gastritis ,mongolia ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Background/Aims: A latex agglutination turbidity (LA) assay to test for serum antibodies has been approved in Japan and Korea for mass screening of Helicobacter pylori infection. In this study, we evaluated the LA assay for diagnosing H. pylori infection and predicting gastric mucosal changes in a Mongolian population. Methods: In total, 484 individuals were classified into H. pylori-positive (n=356) and H. pylori-negative (n=128) groups, as determined by histology and H. pylori culture. Results: The best cutoff, sensitivity, and specificity values for the LA assay were 18.35 U/mL, 74.2%, and 65.6%, respectively. The LA values in the atrophic gastritis group were statistically higher than those in the other groups (healthy, chronic gastritis, intestinal metaplasia, and gastric cancer, p
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.